Literature DB >> 19255691

Pneumocystis jirovecii pneumonia in patients with and without human immunodeficiency virus infection.

Ying-Shih Su1, Jang-Jih J Lu, Cherng-Lih Perng, Feng-Yee Chang.   

Abstract

BACKGROUND AND
PURPOSE: Pneumocystis jirovecii pneumonia is an opportunistic infection capable of causing life-threatening pneumonia in immunocompromised patients. To elucidate the clinical presentation and outcome of this disease in Taiwan, we analyzed the patients with P. jirovecii pneumonia during a 34-month period.
METHODS: We collected data retrospectively from patients with P. jirovecii pneumonia at a medical center in northern Taiwan between January 2004 and October 2006. The diagnosis was made by nested polymerase chain reaction (PCR) analysis of expectorated sputum. Demographics, clinical characteristics, laboratory findings, and outcomes were compared between patients with and without human immunodeficiency virus (HIV) infection.
RESULTS: Forty nine patients were included in this study. The most common underlying diseases were HIV and malignancies. The mean (+/- standard deviation) age of the 49 patients was 54 +/- 20.2 years (range, 5 to 96 years). The mean CD4+ T-lymphocyte count was 110 cells/microL (range, 0-670 cells/microL). Although the mean CD4+ T-lymphocyte count of the non-HIV group was higher than that of the HIV group (165 +/- 78 cells/microL vs 57.5 +/- 97 cells/microL), statistical significance was not obtained (p=0.087). Arterial oxygenation (ratio of arterial oxygenation to fraction of inspired oxygen) was less than 200 mm Hg in 28 patients. Lactate dehydrogenase levels were higher than the normal range in 15 patients. A significantly higher proportion of patients died in the group without HIV compared with the HIV-infected patients (17/34 [50.0%] vs 1/15 [6.7%]; p=0.004).
CONCLUSION: P. jirovecii pneumonia remains a significant problem for immunocompromised patients. The mortality rate for patients without HIV infection was high (50%). Greater alertness with regard to early detection of P. jirovecii in HIV-negative immunosuppressed patients with the application of nested PCR may improve the clinical management and outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19255691

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  9 in total

Review 1.  Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches.

Authors:  Marjorie Bateman; Rita Oladele; Jay K Kolls
Journal:  Med Mycol       Date:  2020-11-10       Impact factor: 4.076

2.  Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay.

Authors:  Philippe M Hauser; Jacques Bille; Cornelia Lass-Flörl; Christian Geltner; Marta Feldmesser; Michael Levi; Hitesh Patel; Victoria Muggia; Barbara Alexander; Martin Hughes; Sarah A Follett; Xiaohui Cui; Flora Leung; Gillian Morgan; Adrian Moody; David S Perlin; David W Denning
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

3.  A new method for the detection of Pneumocystis jirovecii using flow cytometry.

Authors:  J Barbosa; C Bragada; S Costa-de-Oliveira; E Ricardo; A G Rodrigues; C Pina-Vaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-16       Impact factor: 3.267

4.  Development and Evaluation of Rapid and Accurate CRISPR/Cas13-Based RNA Diagnostics for Pneumocystis jirovecii Pneumonia.

Authors:  Yangqing Zhan; Xiaoqing Gao; Shaoqiang Li; Yeqi Si; Yuanxiang Li; Xu Han; Wenjun Sun; Zhengtu Li; Feng Ye
Journal:  Front Cell Infect Microbiol       Date:  2022-06-15       Impact factor: 6.073

5.  Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients: a retrospective study of two centers in China.

Authors:  Fei Guo; Yong Chen; Shuang-Li Yang; Huan Xia; Xing-Wang Li; Zhao-Hui Tong
Journal:  PLoS One       Date:  2014-07-16       Impact factor: 3.240

6.  Diagnosis of Pneumocystis jirovecii Pneumonia in Pediatric Patients in Serbia, Greece, and Romania. Current Status and Challenges for Collaboration.

Authors:  Valentina Arsić Arsenijevic; Timoleon-Achilleas Vyzantiadis; Mihai Mares; Suzana Otasevic; Athanasios Tragiannidis; Dragana Janic
Journal:  J Fungi (Basel)       Date:  2020-04-17

Review 7.  Bendamustine and pneumocystis pneumonia: A systematic review.

Authors:  Atousa Hakamifard; Masoud Mardani; Mohammad Javad Nasiri; Tahereh Gholipur-Shahraki
Journal:  Health Sci Rep       Date:  2022-04-26

8.  Non-HIV Pneumocystis pneumonia: do conventional community-acquired pneumonia guidelines under estimate its severity?

Authors:  Nobuhiro Asai; Shinji Motojima; Yoshihiro Ohkuni; Ryo Matsunuma; Kei Nakasima; Takuya Iwasaki; Tamao Nakashita; Yoshihito Otsuka; Norihiro Kaneko
Journal:  Multidiscip Respir Med       Date:  2012-06-11

9.  Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol.

Authors:  Tarig Mohammed Abkur; Mamoun Saeed; Saad Zeinalabdin Ahmed; Ryan McArthur; Maeve Leahy; Hilary O'Leary; Denis O'Keeffe
Journal:  Clin Case Rep       Date:  2015-02-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.